DE69330351T2 - 5-arylindol-derivate und ihre verwendung als serotonin (5-ht1)-agonisten - Google Patents

5-arylindol-derivate und ihre verwendung als serotonin (5-ht1)-agonisten

Info

Publication number
DE69330351T2
DE69330351T2 DE69330351T DE69330351T DE69330351T2 DE 69330351 T2 DE69330351 T2 DE 69330351T2 DE 69330351 T DE69330351 T DE 69330351T DE 69330351 T DE69330351 T DE 69330351T DE 69330351 T2 DE69330351 T2 DE 69330351T2
Authority
DE
Germany
Prior art keywords
alkyl
aryl
hydrogen
ring
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69330351T
Other languages
English (en)
Other versions
DE69330351D1 (de
Inventor
Eugene Macor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of DE69330351D1 publication Critical patent/DE69330351D1/de
Publication of DE69330351T2 publication Critical patent/DE69330351T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
DE69330351T 1992-11-02 1993-10-19 5-arylindol-derivate und ihre verwendung als serotonin (5-ht1)-agonisten Expired - Fee Related DE69330351T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97075892A 1992-11-02 1992-11-02
PCT/US1993/009790 WO1994010171A1 (en) 1992-11-02 1993-10-19 5-arylindole derivatives and their use as serotonin (5-ht1) agonists

Publications (2)

Publication Number Publication Date
DE69330351D1 DE69330351D1 (de) 2001-07-19
DE69330351T2 true DE69330351T2 (de) 2001-09-20

Family

ID=25517470

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69330351T Expired - Fee Related DE69330351T2 (de) 1992-11-02 1993-10-19 5-arylindol-derivate und ihre verwendung als serotonin (5-ht1)-agonisten

Country Status (27)

Country Link
US (1) US5886008A (de)
EP (2) EP1094064A1 (de)
JP (1) JP2788551B2 (de)
KR (1) KR0163371B1 (de)
CN (1) CN1051313C (de)
AT (1) ATE202102T1 (de)
AU (1) AU685066B2 (de)
BR (1) BR9307348A (de)
CA (2) CA2340999C (de)
CZ (1) CZ283001B6 (de)
DE (1) DE69330351T2 (de)
DK (1) DK0666858T3 (de)
EG (1) EG20396A (de)
ES (1) ES2157224T3 (de)
FI (2) FI111257B (de)
GR (1) GR3036579T3 (de)
HU (1) HU222235B1 (de)
IL (1) IL107386A (de)
MY (1) MY109696A (de)
NO (1) NO309652B1 (de)
NZ (1) NZ257059A (de)
PL (1) PL176091B1 (de)
PT (1) PT666858E (de)
RU (1) RU2134266C1 (de)
TW (1) TW251284B (de)
WO (1) WO1994010171A1 (de)
ZA (1) ZA938137B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
HUT75646A (en) * 1993-08-31 1997-05-28 Pfizer 5-arylindole derivatives and pharmaceutical compositions containing them
CN1067386C (zh) * 1994-02-10 2001-06-20 辉瑞大药厂 作为苯并二氮杂䓬受体位的兴奋剂和拮抗药的5-杂芳基吲哚衍生物
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
CN1184425A (zh) * 1995-03-20 1998-06-10 伊莱利利公司 5-取代-3-(1,2,3,6-四氢吡啶-4-基)-和3-(哌啶-4-基)-1h-吲哚:新型5-ht1f激动剂
US5942536A (en) * 1995-10-10 1999-08-24 Eli Lilly And Company N- 2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT1F agonists
IL133800A0 (en) 1997-07-03 2001-04-30 Du Pont Pharm Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
JP2002519321A (ja) * 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー セロトニン関連系に効果を有するピロリジン、及び、ピロリン誘導体
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
DE60336576D1 (de) 2002-10-30 2011-05-12 Merck Sharp & Dohme Hemmer der akt aktivität
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
AU2004233827B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
AU2004268950A1 (en) * 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine-derivatives as c-kit inhibitors
US7442709B2 (en) * 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
JP5043435B2 (ja) 2003-10-03 2012-10-10 スリーエム イノベイティブ プロパティズ カンパニー アルコキシ置換イミダゾキノリン
WO2005051317A2 (en) 2003-11-25 2005-06-09 3M Innovative Properties Company Substituted imidazo ring systems and methods
DE102004014304A1 (de) * 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen
CA2597092A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
US10604484B2 (en) 2015-04-29 2020-03-31 Janssen Pharmaceutica Nv Indolone compounds and their use as AMPA receptor modulators
JP6804469B2 (ja) 2015-04-29 2020-12-23 ヤンセン ファーマシューティカ エヌ.ベー. ベンゾイミダゾロン及びベンゾチアゾロン化合物並びにampa受容体調節因子としてのそれらの使用
US10513523B2 (en) 2015-04-29 2019-12-24 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators
EP3288940B9 (de) * 2015-04-29 2021-07-21 Janssen Pharmaceutica NV Azabenimidazole und ihre verwendung als ampa-rezeptor-modulatoren
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
CN108137555B (zh) 2015-11-06 2021-02-19 豪夫迈·罗氏有限公司 可用于治疗cns疾病的二氢吲哚-2-酮衍生物
CN108349942B (zh) 2015-11-06 2021-03-30 豪夫迈·罗氏有限公司 用于治疗cns和相关疾病的二氢吲哚-2-酮衍生物
EP3371168B1 (de) 2015-11-06 2020-05-27 H. Hoffnabb-La Roche Ag Indolin-2-on-derivate
EP3371174B1 (de) 2015-11-06 2021-03-17 H. Hoffnabb-La Roche Ag Indolin-2-on-derivate
CN111822047B (zh) * 2020-07-17 2022-05-27 曲阜师范大学 一种磁性介孔聚合离子液体负载催化合成吲哚类衍生物的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
US4983622A (en) * 1984-02-06 1991-01-08 Eli Lilly And Company 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5340838A (en) * 1990-05-04 1994-08-23 Eli Lilly And Company Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
CA2042295A1 (fr) * 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
CA2064815C (en) * 1990-06-07 1999-11-16 Alan Duncan Robertson Therapeutic heterocyclic compounds
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
AU651637B2 (en) * 1990-10-15 1994-07-28 Pfizer Inc. Indole derivatives
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
FR2672602B1 (fr) * 1991-02-12 1993-06-04 Centre Nat Rech Scient Composes derives des beta-carbolines ligands du recepteur des benzodiazepines ayant un effet agoniste inverse et antagoniste vis-a-vis des benzodiazepines et medicaments les contenant.
US5229401A (en) * 1991-09-23 1993-07-20 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino benzo[b]thiophene compounds
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
US5378846A (en) * 1993-06-11 1995-01-03 Russian-American Institute For New Drug Development 1,2,3,4-tetrahydropyrrolo-[1,2-a]-pyrazine derivatives

Also Published As

Publication number Publication date
IL107386A0 (en) 1994-01-25
US5886008A (en) 1999-03-23
BR9307348A (pt) 1999-05-11
CZ110895A3 (en) 1995-11-15
TW251284B (de) 1995-07-11
EP0666858A1 (de) 1995-08-16
CA2148380A1 (en) 1994-05-11
PL176091B1 (pl) 1999-04-30
ZA938137B (en) 1995-05-02
CA2340999C (en) 2005-01-04
EP1094064A1 (de) 2001-04-25
NO309652B1 (no) 2001-03-05
JP2788551B2 (ja) 1998-08-20
EG20396A (en) 1999-02-28
CA2148380C (en) 2001-08-14
CZ283001B6 (cs) 1997-12-17
FI934825A (fi) 1994-05-03
HUT66011A (en) 1994-08-29
WO1994010171A1 (en) 1994-05-11
KR0163371B1 (ko) 1998-12-01
NO951633L (no) 1995-04-28
CN1051313C (zh) 2000-04-12
FI111257B (fi) 2003-06-30
KR950704313A (ko) 1995-11-17
GR3036579T3 (en) 2001-12-31
IL107386A (en) 1999-03-12
AU5329494A (en) 1994-05-24
CN1094727A (zh) 1994-11-09
PT666858E (pt) 2001-09-28
JPH07508759A (ja) 1995-09-28
DE69330351D1 (de) 2001-07-19
DK0666858T3 (da) 2001-08-27
RU2134266C1 (ru) 1999-08-10
AU685066B2 (en) 1998-01-15
ATE202102T1 (de) 2001-06-15
NZ257059A (en) 1997-07-27
ES2157224T3 (es) 2001-08-16
FI20002505A (fi) 2000-11-15
NO951633D0 (no) 1995-04-28
PL308669A1 (en) 1995-08-21
CA2340999A1 (en) 1994-05-11
HU222235B1 (hu) 2003-05-28
EP0666858B1 (de) 2001-06-13
MY109696A (en) 1997-04-30
RU95109927A (ru) 1997-01-10
FI934825A0 (fi) 1993-11-01

Similar Documents

Publication Publication Date Title
ATE202102T1 (de) 5-arylindol-derivate und ihre verwendung als serotonin (5-ht1)-agonisten
DE69413240T2 (de) 5-arylindolderivate
PE34996A1 (es) Nuevo derivado de pirrocarbazol
DE3776044D1 (de) Pyridazinon-derivate.
DE69810373T2 (de) Pyrrolidin Derivate, Anti-ulcus und Antibakterielle Arzneimittel
DE69128272D1 (de) Piperazinderivate
ATE98960T1 (de) 1,8-benzonaphthyridinderivate, ihre herstellung und diese enthaltende zusammensetzungen.
ATE134607T1 (de) Tetrahydronaphtalenderivate, ihre herstellung und ihre therapeutische verwendung
ES2112470T3 (es) Derivados de piridazinona, procedimientos de produccion y utilizacion.
ES2077697T3 (es) Derivados de 1-fenoxicarbonil-2-pirrolidinona y agentes nootropicos.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee